Company intelligence
Noble Life Sciences Inc
Preclinical CRO-in vitro and in vivo testing services for cell and gene therapy, biologics, vaccines, drugs, and devices
About Noble Life Sciences Inc
Noble Life Sciences is a contract research organization (CRO) that provides a full continuum of preclinical drug, vaccine and medical device development services, from initial product discovery to GLP-compliant studies. Our services are designed to help you advance from concept to clinic faster and more efficiently. Noble's state-of-the-art facilities are located in Sykesville, MD in the BioHealth Capital Region. We offer integrated in vitro and in vivo services, including cellular and animal disease model development and experimental design, efficacy, toxicity, biodistribution and product release studies in both small and large animals. Managed by industry experts with years of experience in animal care, Noble's vivarium services group is ready to support your in vivo R&D: we provide custom housing, husbandry, and breeding; facility and program management; and high-level implementation of preclinical drug development services. Noble also offers custom antibody production services as well as tissue and animal sourcing. With an emphasis on quality, our proof-of- concept studies, early safety assessments and other pre-IND services are sure to provide a strong scientific foundation for your preclinical decisions. Noble’s key advantages are our deep expertise and the years of experience of our scientific team, who bring their insights to optimize and expedite our customers’ preclinical studies. With our quality control and expertise in cell- & animal-based models, you can trust Noble scientists to help lead and support your development programs through each phase of the preclinical process.
Verified activity
Signals from Noble Life Sciences Inc
4 published signals
Research & Knowledge
Noble Life Sciences Inc notes new Phase 1/2 results from Memorial Sloan Kettering Cancer Center showing promising activity for daraxonrasib, a therapy targeting multiple RAS mutations in previously treated metastatic lung cancer with over 30% patient response and a median progression-free survival of 8.3 months.
Reported by Noble Life Sciences Inc
Presence & Recognition
Noble Life Sciences Inc is a CRO Services Sponsor for the BioHealth Capital Region Crab Trap Competition, supporting the six finalists including Actuated Medical, Inc., Adidar Health, Inc., Cortexx Medical Intelligence, Lisen Imprinting Diagnostics, Liquet Medical Inc, and Phycin.
Reported by Noble Life Sciences Inc
Presence & Recognition
Noble Life Sciences Inc is attending the BioHealth Capital Region Week 2026 in Rockville, MD, from September 15 to 16.
Reported by Noble Life Sciences Inc